<DOC>
	<DOCNO>NCT02952924</DOCNO>
	<brief_summary>This study sponsor-open , investigator-blinded , participant-blinded , randomize , placebo-controlled , single-ascending dose ( SAD ) multiple-ascending dose ( MAD ) study evaluate safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) RO7049389 follow oral administration healthy volunteer chronic HBV infect participant . The effect food PK RO7049389 effect multiple dose RO7049389 PK single oral microdose midazolam evaluate . The study conduct two part : Part 1 ( 1a [ SAD cohort ] , 1b [ Food-effect SAD cohort ] , 1c [ MAD Cohort ] ) healthy volunteer Part 2 ( Proof mechanism [ POM ] ) chronic HBV infect participant .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics Pharmacodynamics Single Multiple Doses RO7049389 Healthy Volunteers Chronic Hepatitis B Virus ( HBV ) Infected Participants</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Part 1 Healthy Volunteers : Absence evidence active chronic disease follow detailed medical surgical history , complete physical examination include vital sign , 12lead Electrocardiogram ( ECG ) , hematology , blood chemistry , serology urinalysis A Body Mass Index ( BMI ) 18 30 kilogram per square meter ( kg/m^2 ) inclusive Female participant must either surgically sterile postmenopausal least one year For men : agreement remain abstinent use contraceptive measure , agreement refrain donate sperm Part 2 Chronic HBVinfected participant : A BMI 18 30 kg/m^2 inclusive Chronic Hepatitis B infection , define positive test Hepatitis B surface antigen ( HBsAg ) 6 month prior randomization HBV DNA screen great equal ( &gt; /= ) 2 × 10^4 international unit per milliliter ( IU/mL ) Hepatitis B e antigen ( HBeAg ) positive participant , &gt; /=2 × 10^3 IU/mL HBeAgnegative participant Liver biopsy , fibroscan equivalent test obtain within past 6 month demonstrate liver disease consistent chronic HBV infection absence extensive bridging fibrosis absence cirrhosis For men : agreement remain abstinent use contraceptive measure , agreement refrain donate sperm For woman childbearing potential : agreement remain abstinent use nonhormonal contraceptive method result failure rate le ( &lt; ) 1 percent ( % ) per year treatment period least 28 day last dose study drug Part 1 Healthy Volunteers : History symptom clinically significant gastrointestinal , renal , hepatic , bronchopulmonary , neurological , psychiatric , cardiovascular , endocrinological , hematological allergic disease , metabolic disorder , cancer cirrhosis History Gilbert 's syndrome Participants significant acute infection , e.g. , influenza , local infection , acute gastrointestinal symptom clinically significant illness within two week dose administration Any confirm significant allergic reaction ( urticaria anaphylaxis ) drug , multiple drug allergy Any clinically significant concomitant disease condition could interfere , treatment might interfere , conduct study , would , opinion Investigator , pose unacceptable risk participant study Positive test screen follow : Hepatitis A ( HAV IgM Ab ) , Hepatitis B ( HBsAg ) , Hepatitis C ( HCV RNA HCV Ab ) human immunodeficiency virus ( HIV Ab ) Acute narrowangle glaucoma ( MADmidazolam cohort ) Part 2 Chronic HBVinfected participant : History evidence bleed esophageal varix Evidence liver cirrhosis decompensated liver disease ascites , esophageal gastric varix , splenomegaly , nodular liver , jaundice , hepatic encephalopathy History evidence medical condition associate chronic liver disease HBV infection ( e.g. , hemochromatosis , autoimmune hepatitis , alcoholic liver disease , toxin exposure , thalassemia , nonalcoholic steatohepatitis , etc . ) Documented history evidence metabolic liver disease within one year randomization Positive test hepatitis A ( IgM antiHAV ) , hepatitis C , hepatitis D , human immunodeficiency virus History suspicion hepatocellular carcinoma alphafetoprotein &gt; /= Upper limit normal ( ULN ) screen History clinically significant gastrointestinal , cardiovascular , endocrine , renal , ocular , pulmonary , psychiatric neurological disease History organ transplantation Previous concurrent HBV treatment past 6 month Significant acute infection ( e.g. , influenza , local infection ) clinically significant illness within 2 week randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>